Related Experiment Videos
Increased platelet aggregation after heart transplantation: influence of aspirin
M de Lorgeril1, G Dureau, P Boissonnat
1INSERM Unit 63, Bron, France.
Insights
Heart transplant recipients show increased platelet aggregation and aspirin resistance, contributing to graft coronary artery disease. This finding may explain why antiplatelet drugs fail to prevent heart attacks in these patients.
Area of Science:
- Cardiology
- Immunology
- Transplantation
Background:
- Accelerated graft coronary artery disease is a major complication after heart transplantation.
- Current antiplatelet therapies are often ineffective in preventing this condition.
Purpose of the Study:
- To compare ex vivo platelet function in heart transplant recipients versus controls.
- To assess the impact of aspirin on platelet function in these groups.
Main Methods:
- Ex vivo platelet aggregation assays were performed.
- Adenosine diphosphate (ADP) was used as a stimulus.
- Aspirin's inhibitory effect on platelet aggregation was evaluated.
Main Results:
- Heart transplant recipients displayed significantly higher platelet aggregation in response to ADP compared to healthy subjects and non-transplant coronary patients.
- Platelets from heart transplant recipients showed resistance to the antiplatelet effects of aspirin.
Conclusions:
- Elevated platelet hyperaggregation and aspirin resistance in heart transplant recipients may underlie the ineffectiveness of antiplatelet agents.
- These findings suggest novel therapeutic targets for managing graft coronary artery disease.
Abstract:
Accelerated graft coronary artery disease remains the most dramatic complication in long-term survivors of heart transplantation. The main purpose of this study was to evaluate ex vivo platelet function of heart transplant recipients as compared with that of healthy subjects and nontransplant coronary patients. The influence of aspirin, the chief antiplatelet agent, was also evaluated. The heart transplant recipients exhibited a marked platelet hyperaggregation to adenosine diphosphate as compared with the two control groups. In addition, platelets of the heart transplant recipients appeared to be resistant to the inhibitory effect of aspirin. These results could, at least partly, explain the failure of antiplatelet agents to prevent myocardial infarction in these patients.